US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist
  • 9.030
  • +0.440+5.12%
Close Dec 13 16:00 ET
  • 8.920
  • -0.110-1.22%
Post 19:52 ET
642.26MMarket Cap-5.75P/E (TTM)

Altimmune Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
-98.62%5K
-16.67%5K
-76.19%5K
726.47%426K
133.64%37K
18,000.00%362K
-25.00%6K
-34.38%21K
-101.54%-68K
-103.36%-110K
Operating revenue
-98.62%5K
-16.67%5K
-76.19%5K
726.47%426K
133.64%37K
18,000.00%362K
-25.00%6K
-34.38%21K
-101.54%-68K
-103.36%-110K
Cost of revenue
Gross profit
Operating expense
8.17%24.77M
48.50%26.75M
23.04%26.8M
-4.26%83.94M
-7.58%21.24M
-7.48%22.9M
-11.71%18.01M
11.52%21.78M
-2.54%87.67M
-4.08%22.98M
Selling and administrative expenses
10.08%4.97M
17.54%5.6M
17.24%5.31M
5.85%18.14M
13.85%4.33M
0.49%4.51M
7.94%4.76M
2.35%4.53M
11.17%17.13M
0.74%3.81M
-General and administrative expense
10.08%4.97M
17.54%5.6M
17.24%5.31M
5.85%18.14M
13.85%4.33M
0.49%4.51M
7.94%4.76M
2.35%4.53M
11.17%17.13M
0.74%3.81M
Research and development costs
7.70%19.8M
59.62%21.16M
24.57%21.49M
-6.72%65.8M
-11.84%16.91M
-9.25%18.39M
-17.13%13.25M
14.20%17.25M
-5.37%70.54M
-4.98%19.18M
Operating profit
-9.88%-24.77M
-48.53%-26.75M
-23.14%-26.79M
4.82%-83.51M
8.18%-21.2M
8.94%-22.54M
11.71%-18.01M
-11.59%-21.76M
-2.57%-87.74M
-11.65%-23.09M
Net non-operating interest income expense
2.64%1.9M
18.99%2.18M
44.78%2.41M
155.63%7.32M
18.84%1.96M
87.56%1.86M
596.96%1.83M
4,163.41%1.67M
1,345.45%2.86M
832.77%1.65M
Non-operating interest income
1.38%1.91M
18.91%2.18M
44.66%2.41M
156.13%7.35M
33.79%1.96M
78.92%1.88M
459.45%1.84M
7,842.86%1.67M
1,313.79%2.87M
1,176.52%1.47M
Non-operating interest expense
-79.31%6K
-50.00%1K
-50.00%1K
337.50%35K
101.09%2K
-54.69%29K
-96.92%2K
-96.77%2K
60.00%8K
-195.16%-183K
Other net income (expense)
28.57%18K
-167.26%-76K
-163.16%-12K
-38,190.63%-12.25M
-5,613.82%-12.4M
-72.00%14K
352.00%113K
-82.73%19K
99.73%-32K
93.58%-217K
Special income (charges)
----
----
----
---12.42M
----
----
----
----
--0
----
-Less:Impairment of capital assets
----
----
----
--12.42M
----
----
----
----
--0
----
Other non- operating income (expenses)
28.57%18K
-167.26%-76K
-163.16%-12K
618.75%166K
109.22%20K
-72.00%14K
352.00%113K
-82.73%19K
91.44%-32K
-167.90%-217K
Income before tax
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.17%-88.45M
-46.08%-31.64M
12.83%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.55%-84.91M
9.33%-21.66M
Income tax
0
-197K
0
Net income
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.41%-88.45M
-46.08%-31.64M
12.10%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.75%-84.71M
9.33%-21.66M
Net income continuous Operations
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.41%-88.45M
-46.08%-31.64M
12.10%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.75%-84.71M
9.33%-21.66M
Minority interest income
Net income attributable to the parent company
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.41%-88.45M
-46.08%-31.64M
12.10%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.75%-84.71M
9.33%-21.66M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-10.52%-22.85M
-53.42%-24.64M
-21.52%-24.39M
-4.41%-88.45M
-46.08%-31.64M
12.10%-20.67M
20.12%-16.06M
-3.31%-20.07M
12.75%-84.71M
9.33%-21.66M
Basic earnings per share
17.95%-0.32
-9.37%-0.35
15.00%-0.34
8.29%-1.66
-30.23%-0.56
18.75%-0.39
23.81%-0.32
9.09%-0.4
22.98%-1.81
24.56%-0.43
Diluted earnings per share
17.95%-0.32
-9.37%-0.35
15.00%-0.34
8.29%-1.66
-30.23%-0.56
18.75%-0.39
23.81%-0.32
9.09%-0.4
22.98%-1.81
24.56%-0.43
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024 (Q2)Jun 30, 2024 (Q1)Mar 31, 2024 (FY)Dec 31, 2023 (Q4)Dec 31, 2023 (Q3)Sep 30, 2023 (Q2)Jun 30, 2023 (Q1)Mar 31, 2023 (FY)Dec 31, 2022 (Q4)Dec 31, 2022
Total revenue -98.62%5K -16.67%5K -76.19%5K 726.47%426K 133.64%37K 18,000.00%362K -25.00%6K -34.38%21K -101.54%-68K -103.36%-110K
Operating revenue -98.62%5K -16.67%5K -76.19%5K 726.47%426K 133.64%37K 18,000.00%362K -25.00%6K -34.38%21K -101.54%-68K -103.36%-110K
Cost of revenue
Gross profit
Operating expense 8.17%24.77M 48.50%26.75M 23.04%26.8M -4.26%83.94M -7.58%21.24M -7.48%22.9M -11.71%18.01M 11.52%21.78M -2.54%87.67M -4.08%22.98M
Selling and administrative expenses 10.08%4.97M 17.54%5.6M 17.24%5.31M 5.85%18.14M 13.85%4.33M 0.49%4.51M 7.94%4.76M 2.35%4.53M 11.17%17.13M 0.74%3.81M
-General and administrative expense 10.08%4.97M 17.54%5.6M 17.24%5.31M 5.85%18.14M 13.85%4.33M 0.49%4.51M 7.94%4.76M 2.35%4.53M 11.17%17.13M 0.74%3.81M
Research and development costs 7.70%19.8M 59.62%21.16M 24.57%21.49M -6.72%65.8M -11.84%16.91M -9.25%18.39M -17.13%13.25M 14.20%17.25M -5.37%70.54M -4.98%19.18M
Operating profit -9.88%-24.77M -48.53%-26.75M -23.14%-26.79M 4.82%-83.51M 8.18%-21.2M 8.94%-22.54M 11.71%-18.01M -11.59%-21.76M -2.57%-87.74M -11.65%-23.09M
Net non-operating interest income expense 2.64%1.9M 18.99%2.18M 44.78%2.41M 155.63%7.32M 18.84%1.96M 87.56%1.86M 596.96%1.83M 4,163.41%1.67M 1,345.45%2.86M 832.77%1.65M
Non-operating interest income 1.38%1.91M 18.91%2.18M 44.66%2.41M 156.13%7.35M 33.79%1.96M 78.92%1.88M 459.45%1.84M 7,842.86%1.67M 1,313.79%2.87M 1,176.52%1.47M
Non-operating interest expense -79.31%6K -50.00%1K -50.00%1K 337.50%35K 101.09%2K -54.69%29K -96.92%2K -96.77%2K 60.00%8K -195.16%-183K
Other net income (expense) 28.57%18K -167.26%-76K -163.16%-12K -38,190.63%-12.25M -5,613.82%-12.4M -72.00%14K 352.00%113K -82.73%19K 99.73%-32K 93.58%-217K
Special income (charges) ---- ---- ---- ---12.42M ---- ---- ---- ---- --0 ----
-Less:Impairment of capital assets ---- ---- ---- --12.42M ---- ---- ---- ---- --0 ----
Other non- operating income (expenses) 28.57%18K -167.26%-76K -163.16%-12K 618.75%166K 109.22%20K -72.00%14K 352.00%113K -82.73%19K 91.44%-32K -167.90%-217K
Income before tax -10.52%-22.85M -53.42%-24.64M -21.52%-24.39M -4.17%-88.45M -46.08%-31.64M 12.83%-20.67M 20.12%-16.06M -3.31%-20.07M 12.55%-84.91M 9.33%-21.66M
Income tax 0 -197K 0
Net income -10.52%-22.85M -53.42%-24.64M -21.52%-24.39M -4.41%-88.45M -46.08%-31.64M 12.10%-20.67M 20.12%-16.06M -3.31%-20.07M 12.75%-84.71M 9.33%-21.66M
Net income continuous Operations -10.52%-22.85M -53.42%-24.64M -21.52%-24.39M -4.41%-88.45M -46.08%-31.64M 12.10%-20.67M 20.12%-16.06M -3.31%-20.07M 12.75%-84.71M 9.33%-21.66M
Minority interest income
Net income attributable to the parent company -10.52%-22.85M -53.42%-24.64M -21.52%-24.39M -4.41%-88.45M -46.08%-31.64M 12.10%-20.67M 20.12%-16.06M -3.31%-20.07M 12.75%-84.71M 9.33%-21.66M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -10.52%-22.85M -53.42%-24.64M -21.52%-24.39M -4.41%-88.45M -46.08%-31.64M 12.10%-20.67M 20.12%-16.06M -3.31%-20.07M 12.75%-84.71M 9.33%-21.66M
Basic earnings per share 17.95%-0.32 -9.37%-0.35 15.00%-0.34 8.29%-1.66 -30.23%-0.56 18.75%-0.39 23.81%-0.32 9.09%-0.4 22.98%-1.81 24.56%-0.43
Diluted earnings per share 17.95%-0.32 -9.37%-0.35 15.00%-0.34 8.29%-1.66 -30.23%-0.56 18.75%-0.39 23.81%-0.32 9.09%-0.4 22.98%-1.81 24.56%-0.43
Dividend per share
Currency Unit USD USD USD USD USD USD USD USD USD USD
Accounting Standards US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP
Audit Opinions -- -- -- Unqualified Opinion -- -- -- -- Unqualified Opinion --
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme Weight Loss Drugs
Weight Loss Drugs
Intraday-0.11%